The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.

Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.

OncLive spoke with expert investigators to gather insights on the role of AI in cancer care, including oncologic surgery and drug development.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.